US2021379158A1PendingUtilityA1

Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (crhr2)

Assignee: RAQUALIA PHARMA INCPriority: Nov 24, 2017Filed: Aug 17, 2021Published: Dec 9, 2021
Est. expiryNov 24, 2037(~11.3 yrs left)· nominal 20-yr term from priority
Inventors:Mikito Takefuji
A61K 38/2228A61K 38/16A61P 9/04G01N 33/74G01N 2333/726C07K 14/57509A61K 31/167G01N 2800/325C07K 14/575G01N 2500/02C07K 14/72C07K 14/001C07K 16/2869C07K 16/26C07K 14/4703A61K 2039/505A61K 39/3955
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A medicament for preventing or treating heart failure containing an antagonist of the corticotropin releasing hormone receptor 2 as an active ingredient.

Claims

exact text as granted — not AI-modified
1 - 7 . (canceled) 
     
     
         8 . A medicament for preventing or treating heart failure containing an antagonist of the corticotropin releasing hormone receptor 2 as an active ingredient. 
     
     
         9 . The medicament according to  claim 8 , wherein the heart failure is chronic heart failure. 
     
     
         10 . A pharmaceutical composition for preventing or treating heart failure in a mammal comprising an effective amount of the medicament according to  claim 8 . 
     
     
         11 . The pharmaceutical composition according to  claim 10 , further comprising at least one of pharmaceutically acceptable carriers, diluents and excipients. 
     
     
         12 . A method for selecting a subject effective for treatment with the medicament according to  claim 8 , comprising the steps of:
 measuring the serum concentration of the corticotropin releasing hormone receptor 2 agonist in a subject; and   selecting a subject whose measured value is higher than the reference value.   
     
     
         13 . A method of screening drugs for preventing or treating heart failure, comprising the steps of:
 selecting a test substance capable of inhibiting the binding of a corticotropin releasing hormone receptor 2 to its ligand; or   selecting a test substance capable of inhibiting the intracellular signal transduction caused by the binding of a corticotropin releasing hormone receptor 2 to its ligand.

Join the waitlist — get patent alerts

Track US2021379158A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.